Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang JJ, Wang ZF, Tian F, Ning QX

American heart journal26 Jul 2015Cited by 102 (Europe PMC)

PMID26542491DOI10.1016/j.ahj.2015.07.014PepBankPUB-26542491

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with STEMI treated with primary PCI, a 7-day liraglutide course improved left ventricular ejection fraction at 3 months compared with placebo.
In plain wordsIn people with a heart attack treated with a stent procedure, a 7-day liraglutide course improved heart pumping at 3 months compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseChange in left ventricular ejection fraction at 3 months
Study
n = 85
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
1.8 mg 30 minutes before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · 7 daysAs given in this study (human).
Measurements
Difference in change of LVEF
4.1%
liraglutide vs placebo, 3 months
Source sentences
Summary
At 3 months, the primary end point, a difference in change of left ventricular ejection fraction between the two groups was +4.1% (95% CI +1.1% to +6.9%) (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days.
Summary · context
Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
Report a problemFND-2654249101
02HumanRandomized controlled trialEfficacy outcome
In patients with STEMI treated with primary PCI, the no-reflow rate was lower with liraglutide than with placebo but not significantly.
In plain wordsIn people with a heart attack treated with a stent procedure, liraglutide did not significantly change how often blood flow failed to return versus placebo.
Peptide
Liraglutide
Outcome
No significant changeNo-reflow rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.8 mg 30 minutes before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · 7 daysAs given in this study (human).
Measurements
No-reflow rate
7%
liraglutide
No-reflow rate
15%
control
Source sentences
Summary
There was a tendency for a lower rate of no-reflow in liraglutide group that did not reach statistical significance (7% vs control group 15%, P = .20).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days.
Summary · context
Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
Report a problemFND-2654249102
03HumanRandomized controlled trialEfficacy outcome
In patients with STEMI treated with primary PCI, liraglutide significantly improved stress hyperglycemia.
In plain wordsIn people with a heart attack treated with a stent procedure, liraglutide improved high blood sugar linked to the stress of the event.
Peptide
Liraglutide
Outcome
DecreaseStress hyperglycemia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg 30 minutes before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · 7 daysAs given in this study (human).
Source sentences
Summary
Liraglutide could significantly improve stress hyperglycemia (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days.
Summary · context
Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
Report a problemFND-2654249103
04HumanRandomized controlled trialEfficacy outcome
In patients with STEMI treated with primary PCI, liraglutide produced favorable changes in markers of inflammation.
In plain wordsIn people with a heart attack treated with a stent procedure, liraglutide was linked to favorable changes in inflammation markers.
Peptide
Liraglutide
Outcome
Direction not reportedMarkers of inflammation
Study
n: not reported in source
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.8 mg 30 minutes before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · 7 daysAs given in this study (human).
Source sentences
Summary
liraglutide elicited favorable changes in markers of inflammation and endothelial function.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days.
Summary · context
Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
Report a problemFND-2654249104
05HumanRandomized controlled trialEfficacy outcome
In patients with STEMI treated with primary PCI, liraglutide produced favorable changes in markers of endothelial function.
In plain wordsIn people with a heart attack treated with a stent procedure, liraglutide was linked to favorable changes in blood vessel lining markers.
Peptide
Liraglutide
Outcome
Direction not reportedMarkers of endothelial function
Study
n: not reported in source
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
1.8 mg 30 minutes before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · 7 daysAs given in this study (human).
Source sentences
Summary
liraglutide elicited favorable changes in markers of inflammation and endothelial function.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 92 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days.
Summary · context
Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
Report a problemFND-2654249105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

Status unknownNot applicableNCT02650596

Effects of GLP-1 on Chronic Heart Failure

Shi Yangn = 68Jan 2016 to est. Feb 2018

Heart Failure

Trial page ClinicalTrials.govUpdated 8 Jan 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.